See more : Luk Fook Holdings (International) Limited (0590.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmonx Corporation (LUNG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmonx Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- LaSalle LOGIPORT REIT (3466.T) Income Statement Analysis – Financial Results
- Ryman Hospitality Properties, Inc. (RHP) Income Statement Analysis – Financial Results
- Parkway Corporate Limited (PWN.AX) Income Statement Analysis – Financial Results
- PT Batavia Prosperindo Trans Tbk (BPTR.JK) Income Statement Analysis – Financial Results
- SIV Capital Limited (SIV.AX) Income Statement Analysis – Financial Results
Pulmonx Corporation (LUNG)
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 68.68M | 53.66M | 48.42M | 32.73M | 32.60M | 20.00M |
| Cost of Revenue | 17.92M | 13.80M | 12.79M | 11.53M | 10.18M | 7.72M |
| Gross Profit | 50.75M | 39.87M | 35.63M | 21.20M | 22.41M | 12.29M |
| Gross Profit Ratio | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & Development | 18.08M | 15.40M | 13.06M | 7.46M | 6.05M | 6.99M |
| General & Administrative | 89.81M | 77.01M | 64.77M | 44.57M | 34.20M | 20.35M |
| Selling & Marketing | 4.80M | 6.10M | 5.10M | 1.50M | 600.00K | 100.00K |
| SG&A | 94.61M | 83.11M | 69.87M | 46.07M | 34.20M | 20.35M |
| Other Expenses | 0.00 | -396.00K | -585.00K | 3.28M | -617.00K | -916.00K |
| Operating Expenses | 112.69M | 98.50M | 82.93M | 53.53M | 40.25M | 27.34M |
| Cost & Expenses | 130.61M | 112.30M | 95.72M | 65.07M | 50.43M | 35.06M |
| Interest Income | 5.57M | 1.53M | 400.00K | 213.00K | 432.00K | 21.00K |
| Interest Expense | 3.23M | 1.07M | 829.00K | 3.18M | 2.32M | 2.52M |
| Depreciation & Amortization | 1.95M | 4.00M | 3.16M | 400.00K | 1.20M | 270.00K |
| EBITDA | -55.09M | -55.99M | -46.62M | -28.44M | -16.82M | -15.68M |
| EBITDA Ratio | -80.22% | -107.16% | -98.09% | -88.10% | -54.17% | -78.37% |
| Operating Income | -61.94M | -58.64M | -47.30M | -32.33M | -17.84M | -15.05M |
| Operating Income Ratio | -90.19% | -109.27% | -97.70% | -98.77% | -54.73% | -75.24% |
| Total Other Income/Expenses | 1.66M | 67.00K | -1.01M | 314.00K | -2.50M | -3.42M |
| Income Before Tax | -60.27M | -58.57M | -48.32M | -32.02M | -20.34M | -18.47M |
| Income Before Tax Ratio | -87.76% | -109.15% | -99.80% | -97.82% | -62.40% | -92.32% |
| Income Tax Expense | 571.00K | 353.00K | 343.00K | 213.00K | 363.00K | 12.00K |
| Net Income | -60.84M | -58.92M | -48.66M | -32.23M | -20.70M | -18.48M |
| Net Income Ratio | -88.60% | -109.80% | -100.51% | -98.47% | -63.52% | -92.38% |
| EPS | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| EPS Diluted | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| Weighted Avg Shares Out | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
| Weighted Avg Shares Out (Dil) | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
Pulmonx to Report Second Quarter 2023 Financial Results on
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
Pulmonx Corporation (LUNG) Q1 2023 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
7 Nasdaq Small-Cap Stocks Set to Outperform in 2023
Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference
Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023
Why Shares of Pulmonx Rose This Week
Pulmonx Corporation (LUNG) Q4 2022 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports